🎉 M&A multiples are live!
Check it out!

Iovance Biotherapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Iovance Biotherapeutics and similar public comparables like Galapagos, Benevolent AI, and Pharming.

Iovance Biotherapeutics Overview

About Iovance Biotherapeutics

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.


Founded

2007

HQ

United States of America
Employees

838

Website

iovance.com

Financials

LTM Revenue $247M

LTM EBITDA -$336M

EV

$853M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Iovance Biotherapeutics Financials

Iovance Biotherapeutics has a last 12-month revenue of $247M and a last 12-month EBITDA of -$336M.

In the most recent fiscal year, Iovance Biotherapeutics achieved revenue of $164M and an EBITDA of -$352M.

Iovance Biotherapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Iovance Biotherapeutics valuation multiples based on analyst estimates

Iovance Biotherapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $1.2M $164M XXX XXX XXX
Gross Profit n/a -$9.6M XXX XXX XXX
Gross Margin NaN% -6% XXX XXX XXX
EBITDA -$427M -$352M XXX XXX XXX
EBITDA Margin -35949% -214% XXX XXX XXX
Net Profit -$396M -$444M XXX XXX XXX
Net Margin -33296% -271% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Iovance Biotherapeutics Stock Performance

As of April 15, 2025, Iovance Biotherapeutics's stock price is $3.

Iovance Biotherapeutics has current market cap of $1.1B, and EV of $853M.

See Iovance Biotherapeutics trading valuation data

Iovance Biotherapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$853M $1.1B XXX XXX XXX XXX $-1.14

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Iovance Biotherapeutics Valuation Multiples

As of April 15, 2025, Iovance Biotherapeutics has market cap of $1.1B and EV of $853M.

Iovance Biotherapeutics's trades at 3.4x LTM EV/Revenue multiple, and -2.5x LTM EBITDA.

Analysts estimate Iovance Biotherapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Iovance Biotherapeutics and 10K+ public comps

Iovance Biotherapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $853M XXX XXX XXX
EV/Revenue 5.2x XXX XXX XXX
EV/EBITDA -2.4x XXX XXX XXX
P/E -3.0x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -2.3x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Iovance Biotherapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Iovance Biotherapeutics Valuation Multiples

Iovance Biotherapeutics's NTM/LTM revenue growth is 118%

Iovance Biotherapeutics's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.5M for the same period.

Over next 12 months, Iovance Biotherapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Iovance Biotherapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Iovance Biotherapeutics and other 10K+ public comps

Iovance Biotherapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 13699% XXX XXX XXX XXX
EBITDA Margin -214% XXX XXX XXX XXX
EBITDA Growth -18% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -97% XXX XXX XXX XXX
Revenue per Employee $0.2M XXX XXX XXX XXX
Opex per Employee $0.5M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 172% XXX XXX XXX XXX
Opex to Revenue 265% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Iovance Biotherapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Iovance Biotherapeutics M&A and Investment Activity

Iovance Biotherapeutics acquired  XXX companies to date.

Last acquisition by Iovance Biotherapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Iovance Biotherapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Iovance Biotherapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Iovance Biotherapeutics

When was Iovance Biotherapeutics founded? Iovance Biotherapeutics was founded in 2007.
Where is Iovance Biotherapeutics headquartered? Iovance Biotherapeutics is headquartered in United States of America.
How many employees does Iovance Biotherapeutics have? As of today, Iovance Biotherapeutics has 838 employees.
Who is the CEO of Iovance Biotherapeutics? Iovance Biotherapeutics's CEO is Dr. Frederick G. Vogt, J.D..
Is Iovance Biotherapeutics publicy listed? Yes, Iovance Biotherapeutics is a public company listed on NAS.
What is the stock symbol of Iovance Biotherapeutics? Iovance Biotherapeutics trades under IOVA ticker.
When did Iovance Biotherapeutics go public? Iovance Biotherapeutics went public in 2010.
Who are competitors of Iovance Biotherapeutics? Similar companies to Iovance Biotherapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Iovance Biotherapeutics? Iovance Biotherapeutics's current market cap is $1.1B
What is the current revenue of Iovance Biotherapeutics? Iovance Biotherapeutics's last 12-month revenue is $247M.
What is the current EBITDA of Iovance Biotherapeutics? Iovance Biotherapeutics's last 12-month EBITDA is -$336M.
What is the current EV/Revenue multiple of Iovance Biotherapeutics? Current revenue multiple of Iovance Biotherapeutics is 3.4x.
What is the current EV/EBITDA multiple of Iovance Biotherapeutics? Current EBITDA multiple of Iovance Biotherapeutics is -2.5x.
What is the current revenue growth of Iovance Biotherapeutics? Iovance Biotherapeutics revenue growth between 2023 and 2024 was 13699%.
Is Iovance Biotherapeutics profitable? Yes, Iovance Biotherapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.